BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Orthostatic Hypotension Market: The Hospitals Segment is Expected to Register Significant Growth

  Albany NY, United States: Orthostatic hypotension is also called postural hypotension. It occurs when a patient’s blood pressure decreases while standing up or sitting down.

  May 3, 2022

   · 

  5 min read
• Drug Development

  reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

  reMYND NV, a clinical stage company tackling neurodegeneration, announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study.

  May 3, 2022

   · 

  5 min read
• Drug Development

  BioInvent’s BI-1206 to Advance into Expansion Stage of Phase 1/2a Study in NHL after a Productive End-of-Phase 1 FDA Meeting

  BioInvent International AB announces its novel anti-FcyRIIB antibody BI-1206 is progressing into the expansion phase of a Phase 1/2a trial for non-Hodgkin’s lymphoma, following a positive End-of-Phase 1 meeting with the US FDA.

  May 3, 2022

   · 

  5 min read
• Pancreatic Cancer Therapeutics Market: Trends, Opportunities and Regional Outlook

  Albany NY, United States: Pancreatic cancer is characterized by the uncontrolled growth of cells, i.e., malignant cells in the tissues of the pancreas.

  May 3, 2022

   · 

  6 min read
• Drug Development

  Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

  Curium announced it has successfully enrolled and dosed patients in the ECLIPSE Trial.

  May 3, 2022

   · 

  2 min read